iGlarLixi versus basal plus Rapid-Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real-World study.

Rory J McCrimmonAlice Y Y ChengGagik GalstyanKhier DjaballahXuan LiMathieu CoudertJuan P Frias

Published in: Diabetes, obesity & metabolism (2022)

In real-world clinical practice, glycaemic outcomes 6 months after treatment advancement from BI are similar for people with T2D using iGlarLixi versus BI + RAI, with iGlarLixi leading to less weight gain.

Keyphrases

weight gain
type diabetes
clinical practice
body mass index
glycemic control
birth weight
weight loss
insulin resistance
bone marrow
metabolic syndrome
mesenchymal stem cells
gestational age
cell therapy